The use of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)RespiratoryPulmonary Disease
- Registration Number
- ISRCTN65174202
- Lead Sponsor
- South Devon Healthcare NHS Trust (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
1. 35 to 80 years old
2. Diagnosis of COPD as defined by the American Thoracic Society
3. Presentation to the ED with an acute exacerbation of COPD
4. FEV1 less than or equal to 70%
5. FEV1/Forced Vital Capacity (FVC) ratio less than 70%
6. 20 pack year smoking history
Exclusion Criteria
1. Patients requiring intubation, Non-Invasive Ventilation (NIV) or too severe to perform spirometry
2. Arterial pH less than 7.32
3. Clinical history of asthma
4. Known cardiac disease, chronic renal insufficiency or other serious medical condition
5. Pregnant women
6. Clinical or radiographic evidence of pneumonia
7. Hypotension (systolic blood pressure less than 100 mmHg)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Forced expiratory volume in one second (FEV1)
- Secondary Outcome Measures
Name Time Method 1. Forced Vital Capacity (FVC)<br>2. Discharge within 48 hours<br>3. Risk of requiring NIV or intubation or escalation of treatment<br>4. Length of hospital stay - days<br>5. Arterial blood gas tensions<br>6. Modified Borg score